INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 170 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2014. The put-call ratio across all filers is 2.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $775,000 | +241.4% | 6,399 | +219.0% | 0.02% | +266.7% |
| Q1 2017 | $227,000 | -80.4% | 2,006 | -81.2% | 0.01% | -79.3% |
| Q4 2016 | $1,161,000 | +224.3% | 10,690 | +391.3% | 0.03% | +222.2% |
| Q3 2016 | $358,000 | -86.8% | 2,176 | -88.6% | 0.01% | -84.2% |
| Q2 2016 | $2,721,000 | +58.9% | 19,069 | +43.1% | 0.06% | +18.8% |
| Q1 2016 | $1,712,000 | +79.1% | 13,329 | +108.2% | 0.05% | +200.0% |
| Q4 2015 | $956,000 | +90.4% | 6,403 | +208.0% | 0.02% | +77.8% |
| Q2 2015 | $502,000 | -50.0% | 2,079 | -51.0% | 0.01% | -52.6% |
| Q3 2014 | $1,003,000 | +260.8% | 4,242 | +261.3% | 0.02% | +375.0% |
| Q2 2014 | $278,000 | – | 1,174 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |